A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate
Korean Journal of Hematology
; : 73-75, 2010.
Article
in En
| WPRIM
| ID: wpr-720282
Responsible library:
WPRO
ABSTRACT
Imatinib mesylate (IM) is used to treat a wide range of diseases, including Philadelphia chromosome-positive chronic myeloid leukemia (CML), on account of its high tolerability and low incidence of minor adverse events. Hemorrhage is thought to be a rare complication of IM. Recently, IM has been associated with reduced alpha2-plasmin inhibitor and platelet dysfunction. We report here the case of a 33-year-old female patient with CML who experienced subdural hematoma after an incremental increase in IM dosage due to a loss of complete molecular response. This case indicates that physicians should be alert to this atypical cause of headache in patients taking high-dose IM.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Piperazines
/
Pyrimidines
/
Benzamides
/
Blood Platelets
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Philadelphia
/
Incidence
/
Mesylates
/
Imatinib Mesylate
/
Headache
Type of study:
Incidence_studies
/
Prognostic_studies
Limits:
Adult
/
Female
/
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Korean Journal of Hematology
Year:
2010
Type:
Article